Welcome
As a market pioneer, our focus is on the international distribution of the innovative IMPACT-Platform for Autologous Cell Therapies.
About us
IMPACT International GmbH was founded in 2018 to facilitate the international sales of IMPACT Platform for Autologous Cell Therapies and to collaborate with distribution partners across the world. Since the foundation our international network has grown significantly in size and reach.
IMPACT Platform for Autologous Cell Therapies is the revolutionary new platform for the preparation of a broad variety of autologous blood and tissue derivatives.
The innovative IMPACT system is manufactured in Germany. It has been developed and CE-marked by Plasmaconcept AG, Cologne. Plasmaconcept AG maintains a certified quality management system according ISO 13485 and has already certified all IMPACT products according the requirements of the European Medical Device Regulation 2017/745.
IMPACT Worldwide
Interested in becoming a partner and introducing the revolutionary IMPACT platform to your country? Please contact us
Contact
IMPACT International GmbH
Breite Str. 2-4
D-50667 Köln
Phone: +49 (0)221 84 56 25-0
Fax: +49 (0)221 84 56 25-25
